FDA Moves to Facilitate Biosimilar Development
Yesterday, the Food and Drug Administration (FDA) announced long-overdue reforms to the biosimilar approval process that will boost biosimilar development and competition in the United States.
Alex Brill Interviewed by Biosimilars Review & Report
Following the release of the new MGA white paper “The Long-Term Effects of Medicare Price Negotiations on Drug Competition,” Alex Brill spoke with Stanton Mehr at Biosimilars Review & Report.
New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
